-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Pulmonx, Lowers Price Target to $9

Benzinga·05/01/2025 14:37:56
Listen to the news
Piper Sandler analyst Jason Bednar reiterates Pulmonx (NASDAQ:LUNG) with a Overweight and lowers the price target from $10 to $9.